BioTuesdays

Tag - H.C. Wainwright

Markets

HCW ups Constellation Pharma PT to $50 from $18

H.C. Wainwright raised its price target for Constellation Pharmaceuticals (NASDAQ:CNST) to $50 from $18, saying the company’s ASH abstracts lend strong support to a bullish view on CPI-0610’s potential...

November 7, 2019
Markets

HCW starts Aravive at buy; PT $18

H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9. The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to...

October 10, 2019
Markets

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

August 26, 2019
Markets

HCW ups Cesca Therapeutics PT to $6.50 from $1

H.C. Wainwright raised its price target for Cesca Therapeutics (NASDAQ:KOOL) to $6.50 from $1 after the company’s second quarter revenue beat consensus. The stock closed at $3 on Aug. 13. Cesca develops and markets...

August 14, 2019
Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019
Markets

HCW cuts Melinta Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Melinda Therapeutics (NASDAQ:MLNT) to “neutral” from “buy” and removed its price target after the company’s chairman and CEO abruptly resigned on Aug. 9, when the stock dropped 67 cents to...

August 12, 2019
Markets

HCW cuts Autolus PT to $24 from $41

H.C. Wainwright lowered its price target for Autolus Therapeutics plc (NASDAQ:AUTL) to $24 from $41 after significant changes to its pipeline and timelines were disclosed in the company’s second quarter results. The...

August 12, 2019
Markets

HCW cuts Organovo to neutral and removes PT

H.C. Wainwright downgraded Organovo Holdings (NASDAQ:ONVO) to “neutral” from “buy” and removed its price target after the company engaged a financial advisor to assist management in exploring strategic alternatives. The...

August 8, 2019

Subscribe

Sign up to our weekly BioTuesdays newsletter.